CA27.29
Marquette General Health System
HLAB/HOL Code |
CA27 | |
MGH LIS Test No |
576 | |
Schedule |
Monday-Sunday | |
Testing Time |
1-2 days | |
Testing Lab |
Quest Valencia | |
QORR Test Code |
CA27 | |
Type |
1 Red Top (Plain) or SST | |
Volume |
2.0 (0.5) mL | |
Temperature |
Ambient - 7 Day(s)/Refrigerated - 7 Day(s)/Frozen | |
Preservative |
||
Collection Info |
Ambient - 7 Day(s)/Refrigerated - 7 Day(s)/Frozen - 2 Month(s) |
|
Clinical Utilities
CA27.29 is a tumor marker useful in the management of patients with metastatic carcinoma of the breast. It is used to monitor the course of breast cancer, patient response to treatment, and disease recurrence. Elevated serum CA27.29 concentrations are found in 5% of stage I, 29% of stage II, 32% of stage III and 95% of stage IV carcinoma of the breast. Most (96%) patients with a CA27.29 increase of greater than 25% have disease progression. Most (nearly 100%) patients with a CA27.29 decrease of greater than 50% are responding to treatment. CA27.29 is one of several names, including CA15-3, used to refer to breast carcinoma associated antigen. These assays (CA27.29 and CA 15-3) measure the same antigen.
CPT Codes
86300
The CPT codes provided are based on AMA guidelines
and are for informational purposes only. CPT coding is the
sole responsibility of the billing party. Please direct any questions
regarding coding to the payer being billed.
Reference Range
Less than 38 U/mL
Component Information
Additional Comments
Diagnostic code required for third party reimbursement. CA15-3 equivalent. Claims for CA27.29, an FDA approved breast cancer tumor marker, can be submitted to Medicare. For Serial Graphic reporting, use test code #3134SR; you must provide the patient's Social Security Number. New York clients please use test 3134NY when ordering this test.
Questions or Comments email support@mgh.org
Reference Lab Home Page
Laboratory Main Page
Marquette General Health System Home Page